Clinical Trial of Nebulized Hypertonic Saline to Attenuate Post-Traumatic Acute Lung Injury

• Status: Terminated
• Trial end date: 2018-11-06
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the use of nebulized hypertonic saline (aerosolized salt water) as a preventive treatment for post-traumatic acute lung injury (ALI). Both animal and human research indicate that aerosolized salt water might help reduce harmful inflammation with minimal risks.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Denver Health and Hospital Authority
• Collaborators: National Institutes of Health (NIH); University of Colorado, Denver

Criteria

Inclusion Criteria:

• adult 18 ≤ age ≤ 65

• trauma with a 9 ≤ NISS ≤ 36

• ≤10 units of RBC in the first 6 hours (as this is a major risk factor for ARDS and MOF in this population)

Exclusion Criteria:

• Direct or indirect lung injury

• Elevated intracranial pressure requiring treatment, including but not limited to mannitol, intravenous hypertonic saline, and ventricular drainage

• History of severe chronic respiratory disease

• Child-Pugh Class C liver failure

• Prisoners

• Pregnant women